Cary Street Partners Investment Advisory’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,600	Closed	-$37.4K	–	1891
2023 Q2	$37.4K	Hold	1,600	–	–	﹤0.01%	889
2023 Q1	$37.2K	Buy	1,600 +120	+8%	+$3K	﹤0.01%	815
2022 Q4	$37.3K	Buy	+1,480	New	+$39.8K	﹤0.01%	819

Other funds holding IDNA

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Cary Street Partners Investment Advisory's IDNA Position: Q3 2023 in Review

Cary Street Partners Investment Advisory sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q3 2023, closing a stake of 1,600 shares — an estimated $37.4K sold.

Cary Street Partners Investment Advisory first reported a position in IDNA in Q4 2022 and held it in 3 quarters. The position peaked at $37.4K in Q2 2023. 66 funds tracked by Wall St. Rank hold IDNA as of Q3 2023.

Cary Street Partners Investment Advisory reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q3 2023 after selling out during the quarter.
Cary Street Partners Investment Advisory sold 1,600 iShares Genomics Immunology and Healthcare ETF shares in Q3 2023, an estimated $37.4K.
Cary Street Partners Investment Advisory first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2022 and held it in 3 quarters.
Cary Street Partners Investment Advisory's iShares Genomics Immunology and Healthcare ETF position peaked at $37.4K in Q2 2023.
66 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q3 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q3 2023, filed 13 Nov 2023.